… 1 , Taunton R Southwood, Prudence Manners, John Baum, David N Glass, Jose
Goldenberg, Xiaohu He, Jose Maldonado-Cocco, Javier Orozco-Alcala, Anne-Marie Prieur …

Background The frequency and ethnic variation of Henoch-Schönlein purpura, Kawasaki
disease, and rarer vasculitides during childhood are not well characterised. Our aim was to …

The classification of the juvenile arthritides is an evolving process which has yet to achieve
its ultimate goal of delineating biologically distinct disease groups with predictable outcomes …

A proposed definition of juvenile psoriatic arthritis (JPsA) was used to identify definite or
probable JPsA in 35 children. Definite JPsA (24 patients) was defined as arthritis associated, but …

This article describes the development and initial evaluation of an evidence-based transitional
care programme recently implemented in a multicentre controlled trial in the United …

As part of collaborative multi-centre study started in 2000, 7 children in the UK fulfilled the
inclusion criteria for treatment with autologous T cell depleted (TCD) haematopoietic stem cell …

Objective: To assess the provisions made for the transfer of adolescents with juvenile
idiopathic arthritis to adult rheumatology clinics in the UK and the impact of a transitional care …

Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis
(JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to …

The proven effectiveness of biologics and other immunomodulatory products in inflammatory
rheumatic diseases has resulted in their widespread use as well as reports of potential short…

Objective. Since 2004, juvenile idiopathic arthritis (JIA) patients treated with etanercept and/or
MTX have been monitored in the British Society for Paediatric and Adolescent …